{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:53:29Z","timestamp":1775915609612,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"American Parkinson's Disease Association, the Jackson Fellowship to the University of Arizona Department of Neurology"},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["14-02-01-0471"],"award-info":[{"award-number":["14-02-01-0471"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["14-05-1-0807"],"award-info":[{"award-number":["14-05-1-0807"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE-607917"],"award-info":[{"award-number":["CHE-607917"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NINDS-NS-052727"],"award-info":[{"award-number":["NINDS-NS-052727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH #T35HL007479"],"award-info":[{"award-number":["NIH #T35HL007479"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008227","name":"ARCS Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.neuropharm.2018.09.005","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T09:58:05Z","timestamp":1536314285000},"page":"260-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia"],"prefix":"10.1016","volume":"141","author":[{"given":"Andrew J.","family":"Flores","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell J.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon K.","family":"Root","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate L.","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Heien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Polt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.09.005_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neulet.2015.11.047","article-title":"Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model","volume":"612","author":"Bartlett","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1006\/nbdi.2000.0375","article-title":"Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys","volume":"8","author":"Bezard","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.expneurol.2012.04.017","article-title":"Influence of corticostriatal \u03b4-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats","volume":"236","author":"Billet","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib5","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1021\/jm000077y","article-title":"Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability","volume":"43","author":"Bilsky","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib7","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa","volume":"94","author":"Bordet","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib8","doi-asserted-by":"crossref","first-page":"27084","DOI":"10.1016\/S0021-9258(19)74221-5","article-title":"Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin","volume":"268","author":"Breslin","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib10","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1592\/phco.29.12.1452","article-title":"Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease","volume":"29","author":"Chen","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"1670","key":"10.1016\/j.neuropharm.2018.09.005_bib13","article-title":"Pharmacological treatment of Parkinson disease","volume":"311","author":"Connolly","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/271178a0","article-title":"Evidence for a long Leu-enkephalin striopallidal pathway in rat brain","volume":"271","author":"Cuello","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib6","first-page":"1261","volume":"266","author":"Do Carmo","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/exnr.1997.6431","article-title":"Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression","volume":"144","author":"Duty","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1124\/jpet.104.069393","article-title":"Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides","volume":"311","author":"Elmagbari","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0006-8993(91)90667-K","article-title":"Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats","volume":"552","author":"Engber","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000542-198204000-00011","article-title":"Opiate receptor mediation of ketamine analgesia","volume":"56","author":"Finck","year":"1982","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2014.02.004","article-title":"Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model","volume":"564","author":"Flores","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/mds.10693","article-title":"Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease","volume":"19","author":"Fox","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib23","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson's disease","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib25","series-title":"The Delta Receptor","first-page":"231","article-title":"Mixed opioid receptor agonists as a new class of agents for the treatment of moderate to severe pain","author":"Gengo","year":"2003"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib27","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.parkreldis.2004.11.005","article-title":"Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors","volume":"11","author":"Guigoni","year":"2005","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35075076","article-title":"BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization","volume":"411","author":"Guillin","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib30","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","article-title":"Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa","volume":"22","author":"Hauser","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","article-title":"Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat","volume":"155","author":"Henry","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"\u039c- and \u03b4-opioid receptor antagonists reduce levodopa-induced dyskinesia in the mptp-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease","volume":"183","author":"Henry","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/exnr.2001.7763","article-title":"Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease","volume":"172","author":"Hille","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib35","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Holloway","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib37","article-title":"A simple sequentially rejective multiple test procedure","author":"Holm","year":"1979","journal-title":"Scand. J. Stat."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib38","series-title":"Principles of Treatment in Parkinson's Disease. Philadelphia, PA","author":"Jenner","year":"2005"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","article-title":"Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD","volume":"71","author":"Katzenschlager","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00702-002-0715-6","article-title":"Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism","volume":"109","author":"Klintenberg","year":"2002","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib41","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mds.23631","article-title":"The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease","volume":"26","author":"Koprich","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib42","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(97)24049-3","article-title":"Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease","volume":"350","author":"Krack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib1a","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2018.06.024","article-title":"Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: implications for L-DOPA-induced dyskinesia","volume":"138","author":"Lanza","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4155\/fmc.11.195","article-title":"Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins","volume":"4","author":"Li","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(95)90062-4","article-title":"Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation","volume":"345","author":"Limousin","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0306-4522(98)00411-4","article-title":"Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms","volume":"88","author":"Lindskog","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/jpet.110.172866","article-title":"In vivo characterization of MMP-2200, a mixed \u03b4\/\u03bc opioid agonist, in mice","volume":"336","author":"Lowery","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2012.10.029","article-title":"CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study","volume":"531","author":"Mabrouk","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jnnp.70.4.554","article-title":"High dose naltrexone for dyskinesias induced by levodopa","volume":"70","author":"Manson","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0003-2697(80)90101-3","article-title":"Simultaneous determination of catecholamines and unconjugated 3,4-dihydroxyphenylacetic acid in brain tissue by ion-pairing reverse-phase high-performance liquid chromatography with electrochemical detection","volume":"104","author":"Mefford","year":"1980","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib53","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1016\/j.neuropsychologia.2008.07.011","article-title":"A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism","volume":"46","author":"Moustafa","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0306-4522(94)00606-6","article-title":"Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease","volume":"66","author":"Nisbet","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1471-4159.1995.65010125.x","article-title":"Differential regulation of D1 dopamine receptor- and of A2a adenosine receptor-stimulated adenylyl cyclase by \u03bc-, \u03b41-, and \u03b42-opioid agonists in rat caudate putamen","volume":"65","author":"Noble","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib56","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1471-1931(00)00028-8","article-title":"Pathophysiology of the basal ganglia in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib57","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib58","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neuropharm.2010.01.003","article-title":"MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism","volume":"58","author":"Paquette","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib59","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib60","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib61","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib62","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/mds.870090410","article-title":"Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease","volume":"9","author":"Rascol","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib63","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2006.08.002","article-title":"Opioids and motor complications in Parkinson's disease","volume":"27","author":"Samadi","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1471-4159.1984.tb02698.x","article-title":"Evidence for a selective processing of proenkephalin B into different opioid peptide forms in particular regions of rat brain and pituitary","volume":"42","author":"Seizinger","year":"1984","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2016.03.024","article-title":"Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats","volume":"280","author":"Sgroi","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib68","first-page":"435","article-title":"Dopamine D3 receptor modulates l-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling","volume":"27","author":"Sol\u00eds","year":"2017","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2018.09.005_bib69","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.0953-816x.2001.01743.x","article-title":"Persistent changes in striatal gene expression induced by long-term l -DOPA treatment in a rat model of Parkinson's disease","volume":"14","author":"Westin","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.09.005_bib70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.brainres.2011.07.038","article-title":"Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease","volume":"1413","author":"Yue","year":"2011","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818306282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818306282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:15:35Z","timestamp":1712319335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818306282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":71,"alternative-id":["S0028390818306282"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.09.005","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}